Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics, (Nasdaq: MCRB), announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16 at 9:20 a.m. ET. The company will provide a corporate overview during this event.
A live audio webcast will be accessible on Seres' website, with a replay available one hour post-event for 21 days.
Seres is recognized for its innovative microbiome therapeutics, including the SER-109 program, which has received Breakthrough Therapy designation from the FDA for treating recurrent C. difficile infection.
Seres Therapeutics (Nasdaq: MCRB) announced the voluntary discontinuation of patient enrollment in the MCGRAW study, focusing on SER-401 and nivolumab for metastatic melanoma. This decision follows challenges in enrollment amidst the COVID-19 pandemic. Although the preliminary results from 10 subjects indicated that SER-401 was safe and well-tolerated, the company will deprioritize its development. Seres aims to leverage insights from this study to advance future oncology programs and continues its research in microbiome therapeutics.
Seres Therapeutics (MCRB) reported its Q4 and full year 2020 results, confirming progress in its microbiome therapeutics portfolio. Key highlights include the advancement of SER-109 towards a Biologics License Application (BLA) and achieving target enrollment for the SER-287 ECO-RESET Phase 2b study. SER-109 demonstrated an 88% sustained clinical response in a Phase 3 study for recurrent C. difficile infection, with a significant reduction in recurrence rates. The company enters 2021 with a solid financial position and a robust pipeline targeting multiple diseases.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the successful enrollment of 201 patients in the Phase 2b ECO-RESET clinical trial for SER-287, targeting mild-to-moderate ulcerative colitis (UC). This study aims to assess clinical remission and endoscopic improvement after treatment. The FDA has indicated that this trial may support a Biologics License Application (BLA). The company anticipates sharing topline results in mid-2021, highlighting SER-287's potential as a new therapeutic approach amidst a significant unmet need for safer UC treatments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in two upcoming investor conferences. The Cowen 41st Annual Health Care Conference is set for March 2, 2021, featuring a Microbiome panel discussion and 1x1 meetings. The Chardan 3rd Annual Microbiome Medicines Summit will take place on March 8, 2021, where management will present a corporate overview at 2:30 p.m. ET and conduct 1x1 meetings. An audio webcast for the Chardan presentation will be available on Seres’ website. The company is at the forefront of microbiome therapeutics, with notable programs for recurrent C. difficile infection and ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 2, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 results. The company is a leader in microbiome therapeutics, focusing on multifunctional bacterial therapeutics. Notably, Seres’ SER-109 program has shown positive pivotal clinical results and received Breakthrough Therapy and Orphan Drug designations from the FDA. Additionally, SER-287 is under Phase 2b evaluation for ulcerative colitis, while other programs are in various stages of clinical trials.
Seres Therapeutics (Nasdaq: MCRB) announced new findings from its SER-109 Phase 3 ECOSPOR III clinical study related to recurrent C. difficile infection. The study demonstrated rapid engraftment of SER-109-derived bacteria in the gastrointestinal tract, achieving significant metabolic changes that create an unfavorable environment for C. difficile growth. The data revealed an 88.9% sustained clinical response rate at eight weeks post-treatment, with no serious adverse events reported. SER-109 has received FDA Breakthrough Therapy and Orphan Drug designations.
Seres Therapeutics (Nasdaq: MCRB) announced promising results from its Phase 1b trial of SER-287 for treating active mild-to-moderate ulcerative colitis (UC). The study demonstrated a 40% clinical remission rate in patients receiving daily SER-287 compared to 0% in the placebo group. Data highlighted SER-287's safety and favorable tolerability profile, with no serious adverse events noted. The ongoing Phase 2b ECO-RESET study continues to enroll patients, aiming to provide topline results in late 2021. FDA Fast Track designation for SER-287 reinforces its potential as a transformative therapy for UC.
Seres Therapeutics (Nasdaq: MCRB) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14 at 11:40 a.m. ET. A live audio webcast will be accessible in the ‘Investors and Media’ section of their website, with a replay available an hour post-event for 21 days.
Seres is focused on microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for C. difficile infection and receiving FDA Breakthrough Therapy status. Other programs include SER-287 for ulcerative colitis and SER-401 for metastatic melanoma.
Seres Therapeutics (Nasdaq: MCRB) has announced participation in two virtual investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will take place on December 1, 2020, featuring management in 1x1 meetings and a fireside chat available from November 23, 2020. The 3rd Annual Evercore ISI HealthCONx Virtual Conference is scheduled for December 2, 2020, also including management 1x1 meetings. Seres is a leader in microbiome therapeutics with advanced programs for recurrent C. difficile infection and ulcerative colitis.